Home Featured Page 254

Featured

Latest

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative...

Virtual Reality and Psychedelic Synergy

Adding to their Expert Team, Albert Labs Announces the Formation and...

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat...

Silo Pharma Submits Application for NASDAQ up-listing

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing...

PT245 – Robin Carhart-Harris – Psychedelics, Entropy, and Plasticity

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome...

MagicMed to Be Acquired by Nasdaq-Listed Company

1...253254255...306 Page 254 of 306

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative...

Virtual Reality and Psychedelic Synergy

Adding to their Expert Team, Albert Labs Announces the Formation and...

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat...

Silo Pharma Submits Application for NASDAQ up-listing

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing...

PT245 – Robin Carhart-Harris – Psychedelics, Entropy, and Plasticity

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome...

MagicMed to Be Acquired by Nasdaq-Listed Company

EDITOR PICKS

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY